Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 16;8(10):1697.
doi: 10.3390/jcm8101697.

The Association of Glucocorticosteroid Treatment with WBC Count in Patients with COPD Exacerbation

Affiliations

The Association of Glucocorticosteroid Treatment with WBC Count in Patients with COPD Exacerbation

Amit Frenkel et al. J Clin Med. .

Abstract

Systematic glucocorticosteroids (GCS) are used to treat chronic obstructive pulmonary disease (COPD) and can cause leukocytosis. Distinguishing the effect of GCS on leukocyte level from infection-induced leukocytosis is important. We sought to quantify the effect of chronic GCS treatment on leukocytosis level in patients with COPD exacerbation. We reviewed the records of patients with COPD exacerbation and fever hospitalized in a tertiary medical center in 2003-2014. Patients were classified according to the GCS treatment they received: chronic GCS treatment (CST), acute GCS treatment (AST), and no prior GCS treatment (NGCS). We used the eosinophil absolute count as a marker of compliance and efficacy of steroid treatment. The primary outcome was the maximal white blood cell (WBC) count within the first 24 h of admission. Of 834 patients, 161 were categorized as CST, 116 AST, and 557 NGCS. The overall maximal leukocyte count was higher and the eosinophil count lower in the two GCS therapy groups. In patients with COPD exacerbation and fever, acutely treated with GCS, the mean increase in the WBC count was more evident when the eosinophils were undetectable (absolute count of zero). This supports leukocytosis level as a marker of disease course in COPD and fever.

Keywords: chronic obstructive pulmonary disease (COPD); eosinophils; glucocorticosteroids (GCS); leukocytosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Maximum WBC count as a function of maximum body temperature for COPD patients receiving acute steroid treatment, chronic steroid treatment or no steroid treatment.

References

    1. Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W., Anderson P., Morgan N.A. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. 1999;340:1941–1947. doi: 10.1056/NEJM199906243402502. - DOI - PubMed
    1. Walters J.A., Walters E.H., Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005;3:005374. doi: 10.1002/14651858.CD005374. - DOI - PubMed
    1. Altman L.C., Hill J.S., Hairfield W.M., Mullarkey M.F. Effects of Corticosteroids on Eosinophil Chemotaxis and Adherence. J. Clin. Investig. 1981;67:28–36. doi: 10.1172/JCI110024. - DOI - PMC - PubMed
    1. Cheng S.L. Blood eosinophils and inhaled corticosteroids in patients with COPD: Systematic review and meta-analysis. Int. J. Chronic Obstr. Pulm. Dis. 2018;13:2775–2784. doi: 10.2147/COPD.S175017. - DOI - PMC - PubMed
    1. Frenkel A., Kachko E., Cohen K., Novack V., Maimon N. Estimations of a degree of steroid induced leukocytosis in patients with acute infections. Am. J. Emerg. Med. 2018;36:749–753. doi: 10.1016/j.ajem.2017.10.003. - DOI - PubMed

LinkOut - more resources